VACCITECH PLC logo

VACC

VACCITECH PLC

$2.3

Earnings Summary

Revenue
$-0Mn
Net Profits
$-15.11Mn
Net Profit Margins
1511300%

Highlights

Revenue:

VACCITECH PLC’s revenue fell -100.28% since last year same period to $-0Mn in the Q4 2021. On a quarterly growth basis, VACCITECH PLC has generated -105.26% fall in its revenue since last 3-months.

Net Profits:

VACCITECH PLC’s net profit fell -44.55% since last year same period to $-15.11Mn in the Q4 2021. On a quarterly growth basis, VACCITECH PLC has generated -231.64% fall in its net profits since last 3-months.

Net Profit Margins:

VACCITECH PLC’s net profit margin jumped 51163.99% since last year same period to 1511300% in the Q4 2021. On a quarterly growth basis, VACCITECH PLC has generated 6401.23% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the VACCITECH PLC post its latest quarter earnings

EPS Estimate Current Quarter
-0.38
EPS Estimate Current Year
-0.38

Highlights

EPS Estimate Current Quarter:

VACCITECH PLC’s earning per share (EPS) estimates for the current quarter stand at -0.38 - a 4.38% jump from last quarter’s estimates.

EPS Estimate Current Year:

VACCITECH PLC’s earning per share (EPS) estimates for the current year stand at -0.38.

Key Ratios

Key ratios of the VACCITECH PLC post its Q4 2022 earnings

Earning Per Share (EPS)
0

Highlights

Earning Per Share (EPS):

VACCITECH PLC’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q4 2022. This indicates that the VACCITECH PLC has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2023-03-24
-0.38
0
100%
2022-08-09
-0.32
0.41
226.82%
2022-11-10
-0.4
0
100%
2022-05-11
-0.31
0.07
121.94%

Company Information

Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The company’s proprietary platform comprises proprietary modified simian adenoviral vectors, known as ChAdOx1 and ChAdOx2, as well as the well-validated Modified Vaccinia Ankara, or MVA, boost vector, both with demonstrable tolerability profiles and without the ability to replicate in humans. The combination of a ChAdOx prime treatment with subsequent MVA boost has consistently generated significantly higher magnitudes of CD8+ T cells compared with other technologies and approaches. The company has a broad pipeline of both clinical and preclinical stage therapeutic programs in solid tumors and viral infections and prophylactic viral vaccine programs. Vaccitech co-invented a COVID-19 vaccine with the University of Oxford, now approved for use in many territories and exclusively licensed worldwide to AstraZeneca through Oxford University Innovation, or OUI. Vaccitech is entitled to receive a share of the milestones and royalty income received by OUI from AstraZeneca.

Organisation
VACCITECH PLC
Headquarters
The SchrOedinger Building, Oxford, United Kingdom, OX4 4GE
Employees
72
Industry
Healthcare

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*